白藜芦醇对肺癌紫杉醇耐药细胞的增殖抑制作用及其机制

doi:10.3969/j.issn.1004-616x.2018.03.007

Abstract

Abstract: OBJECTIVE: To study mechanisms in sensitivity of paclitaxel-resistant human lung adenocarcinoma cells from treatment with resveratrol. METHODS: A549/Taxol-R,a human lung adenocarcinoma cell line that resist paclitaxel,was established and treated with different concentrations of resveratrol and paclitaxel alone or in combination. MTT assay was performed and SPSS was used to calculate IC₅₀ of A549/Taxol-R to paclitaxel. Change of IC₅₀ was determined after treatment with resveratrol at different concentrations. Apoptosis rates were detected with flow cytometry. Expressions of Bax,Bcl-2 and Caspase-3 were detected by Western blot. RESULTS: The inhibitory rate of resveratrol to A549/Taxol-R cells was dependent on concentration and time. After treated with resveratrol,the IC₅₀ of paclitaxel on A549/Taxol-R cells decreased from (17.50±1.24) μg/mL to (4.18±0.62) μg/mL. The apoptosis and necrosis rates of A549/Taxol-R cells that were treated with combined resveratrol and paclitaxel were higher than those that treated with single drugs (P < 0.05). Expression of Bax and Caspase3 in the combined treatment group was higher than that in the single treatment group,while expression of Bcl-2 was relatively down-regulated (P < 0.05). CONCLUSION: Resveratrol may increase sensitivity of paclitaxel-resistant human lung adenocarcinoma cells to paclitaxel by promoting cell apoptosis. The mechanism may be related to promotion of expression of Bax and Caspase3 and down-regulation of Bcl-2 expression.

Key words: lung cancer, drug resistance, paclitaxel, resveratrol

CLC Number:

R734.2

WU Yilan, WANG Han. Inhibition of proliferation by resveratrol in paclitaxel-resistant lung adenocarcinoma cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 200-203,208.

References

[1] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] BOCCI G,DI PAOLO A,DANESI R. The pharmacological bases of the antiangiogenic activity of paclitaxel[J]. Angiogenesis,2013,16:481-492.
[3] MILANE L,DUAN Z,AMIJI M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells[J]. Mol Pharm,2011,8(1):185-203.
[4] GUERRERO R F,GARCIA-PARRILLA M C,PUERTAS B,et al. Wine,resveratrol and health:a review[J]. Nat Prod Commun,2009,4(5):635-658.
[5] BOSCOLO P,DEL SIGNORE A,SABBIONI E,et al. Effects of resveratrol on lymphocyte proliferation and cytokine release[J]. Ann Clin Lab Sci,2003,33(2):226-231.
[6] ATHAR M,BACK J H,KOPELOVICH L,et al. Multipe molecular targets of resveratrol:Anti-carcinogenic mechanisms[J]. Arch Biochem Biophys,2009,486(2):95-102.
[7] KUNDU J K,SURH Y J. Cancer chemopreventive and therapeutic potential of resveratrol:mechanistic perspectives[J]. Cancer Lett,2008,269(2):243-261.
[8] AL-ABD A M,MAHMOUD A M,EL-SHERBINY G A,et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro[J]. Cell Prolif,2011,44:591-601.
[9] SUN Q L,SHA H F,YANG X H,et al. Comparative proteomic analysis of paclitaxel sensitive A549 lung adeno-carcinoma cell line and its resistant counterpart A549-Taxol[J]. J Cancer Res Clin Oncol,2011,137(3):521-532.
[10] SNOW K,JUDD W. Characterisation of adriamycin-and amsacrine-resistant human leukaemic T cell lines[J]. Br J Cancer,1991,63(1):17-28.
[11] FULDA S,DEBATIN K M. Resveratrol-mediated sensitization to trail-induced apoptosis depends on death receptor and mitochondrial signaling[J]. Eur J Cancer,2005,41(5):786-789.
[12] JANG M,CAI L,UDEANI G O,et al. Cancer chemo-preventive activity of resveratrol,a natural product derived from grapes[J]. Science,1997,275(5297):218-220.
[13] SCHINDLER C K,SHINODA S,SIMON R P,et al. Subceller distribution ofBcl-2 family protein and 14-3-3 within the hippocampus during seizure-induced neuronal death in the rat[J]. Neurosci Lett,2004,356(3):163-166.
[14] WANG H,WANG H,LIANG J,et al. Cell-penetrating apoptotic peptide/p53 DNA nanocomplexas adjuvant therapy for drug-resistant breast cancer[J]. Mol Pharm,2014,11:3352-3360.
[15] REED J C. Proapoptotic multidomain Bcl-2/Bax family proteins:mechanisms,physiological roles,and therapeutic opportunities[J]. Cell Death and Differ,2006,13:1378-1386.
[16] CHEN J H,CAO J L,CHU Y L,et al. T-2 toxin-induced apoptosis involvingFas,p53,Bcl-2,Bax and caspase-3 signaling pathways in humanchondrocytes[J]. Zhejiang Univ Sci B,2008,9:455-463.
[17] SON J K,VARADARAJAN S,BRATTON S B. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1[J]. Cell Death Differ,2010,17(8):1288-1301.
[18] RUDNER J,JENDROSSEK V,LAUBER K,et al. Type I and type Ⅱ reactions in TRAIL-induced apoptosis-results from dose-response studies[J]. Oncogene,2005,24(1):130-140.
[19] 郑国华,李会庆. 大蒜油和白藜芦醇联合应用对胃癌细胞抑制作用及其机制[J]. 福建中医学院学报,2006,16(6):34-36.
[20] 郑国华,李颢,李会庆. 大蒜油和白藜芦醇联合应用诱导胃癌细胞凋亡[J]. 中国公共卫生,2005,21(10):1205-1207.
[21] 郑国华,吴异兰,谌海英. 白藜芦醇对裸鼠移植瘤bcl-2与bax基因表达影响[J]. 中国公共卫生,2011,27(8):996-998.

Inhibition of proliferation by resveratrol in paclitaxel-resistant lung adenocarcinoma cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[2]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[3]	ZHAO Junwei, HUA Chenfeng, SHANG Pingping, XIE Fuwei, LI Xiang. Induction of oxidative stress by arsenious acid As(Ⅲ) in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 28-31.
[4]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[5]	ZHANG Fan, LIU Guangchao, ZHANG Zhihan, LIU Fangfang, XIE Qi, GAO Shuqing. Effect of ketogenic diet on growth of subcutaneously transplanted human lung cancer in nude mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 286-291.
[6]	WAN Yingxin, ZHANG Ping, LI Nan. Effect of sodium selenite and resveratrol on anti-oxidant and cyclin in lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 459-463.
[7]	CAO Yu, ZHANG Qiaoye, HUA Rui, MA Xiaoling, WANG Xu, NI Juan. Effects of resveratrol on proliferation and genomic instability of human colon cells NCM460 and SW620 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 283-288.
[8]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[9]	ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.
[10]	WU Wen, LI Ping, ZUO Ran, ZENG Qingbo, WU Desheng, XIE Ni, LONG Dingxin, YUAN Jianhui. Correlation between polymorphism of DNA methyltransferase 3B-149C>T and cancer risk:a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 102-110.
[11]	MA Bangjing, HAO Xianglin, HAN Fei, CHEN Hongqiang, LIU Jinyi, CAO Jia, ZHANG Aihua. Inhibition of proliferation and migration of lung adenocarcinoma cells by SOX30 gene via regulation of DSC3 gene [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 165-170,175.
[12]	PENG Hui, MA Shumei, HONG Weiwei, SUI Jing, ZHANG Yanqiu, LIANG Geyu. Regulatory mechanism of miR-202 on proliferation of A549 lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 454-459.
[13]	LIU Hao, ZHAO Yingying, JIN Ping, XU Gaixia, GUO Yuran, ZHANG Ke, WANG Xiaomei, ZHANG Lei. Histone deacetylase inhibitor restrained proliferation of human cervical cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(5): 335-339.
[14]	ZHANG Jing, TENG Yu, ZHAO Xiaoting, JIANG Mei, YUE Wentao. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 245-250.
[15]	ZHU Ting, WAN Lili, LIU Litao, RUAN Haiying, RAO Xi, XIE Ni. ABCG2-siRNA loaded magnetic nanoparticles enhanced therapeutic effect of adriamycin on multidrug resistant breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(3): 199-204.